The Peptide Reference
The Peptide Reference
References
Reference/IGF-1Ec splice variant C-terminal peptide

MGF

Mechano Growth Factor · IGF-1 Splice Variant

research use only

Non-pegylated IGF-1 splice variant produced locally in muscle tissue following mechanical stress. Has a very short half-life compared to PEG-MGF, requiring more frequent administration or localized injection.

Satellite cell activation for muscle repairRecovery support following mechanical stressLocalized tissue regenerationNatural upregulation after exercise
01

Overview

Non-pegylated IGF-1 splice variant produced locally in muscle tissue following mechanical stress. Has a very short half-life compared to PEG-MGF, requiring more frequent administration or localized injection.

Activates muscle satellite stem cells via receptor binding, stimulating MAPK/ERK signaling. Enhances protein synthesis and promotes muscle fiber repair. The E-peptide domain exhibits distinct activity from mature IGF-1.

02

Research indications

What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.

Muscle Repair3
Satellite Cell Activation

Primary mechanism activating dormant muscle satellite cells which fuse to damaged fibers.

Large
Local Muscle Recovery

Short half-life means effects are concentrated at injection site.

Moderate
Post-Exercise Recovery

Naturally upregulated after mechanical stress; supplementation enhances repair processes.

Moderate
Tissue Regeneration2
Tendon Healing

Animal studies suggest improved tendon injury outcomes when applied locally.

Small
Bone Regeneration

Research indicates potential for bone healing via osteoblast regulation.

Small
i

A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.

Quick factsreference only
Class
IGF-1Ec splice variant C-terminal peptide
Chain length
24 residues
Molecular weight
2888 Da
Half-life
~6 min
Typical dose
100-300mcg per injection
Frequency
Daily, immediately post-workout
Cycle length
8-12 weeks
Storage
Refrigerate at 2-8°C; use within 30 days
03

Molecular data

Type
IGF-1Ec splice variant C-terminal peptide
Molecular weight
2888 Da
Chain length
24 residues
Half-life
6 min
04

Dosing reference

Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.

ContextRouteAmountFrequency
Standard ProtocolIM into target muscle100-300mcgDaily, post-workout
Progressive TitrationIM bilateral100mcg → 300mcgDaily, increasing weekly
Localized RecoveryIM into worked muscle groups200-300mcgImmediately post-workout
05

Interactions

PEG-MGF

Same active peptide with different half-lives. Combining is redundant; choose one based on protocol preference.

monitor
IGF-1 LR3

Both target IGF-1 pathways; combining risks receptor overstimulation.

monitor
BPC-157

Complementary mechanisms. BPC-157 promotes angiogenesis; MGF activates satellite cells.

synergistic
TB-500

TB-500 reduces inflammation and promotes cell migration; MGF activates muscle stem cells.

synergistic
06

Quality checklist

  • White or off-white fluffy cake appearance
  • Crystal clear solution after reconstitution
  • Certificate of Analysis with HPLC purity >98%
  • !Minor clumping that dissolves with gentle swirling
  • ×Collapsed or discolored powder
  • ×Persistent cloudiness or visible particles
07

What to expect

ImmediateVery short half-life means localized effects at injection site within minutes
Week 1-2Reduced muscle soreness in targeted areas; subtle recovery improvements
Week 4-8Improved recovery in targeted muscles; enhanced training capacity
08

Safety

Commonly reported2
  • Injection site soreness
  • Mild fatigue
Stop and seek advice4
  • Any unusual growths, lumps, or rapid tissue changes
  • Severe injection site reactions
  • Persistent headaches or vision changes
  • Signs of hypoglycemia
Contraindications3
  • Any history of cancer or neoplastic disease
  • Pregnancy or breastfeeding
  • Uncontrolled diabetes
09

FAQ

Why is MGF injected directly into muscles post-workout?

MGF has a 5-7 minute half-life and activates satellite stem cells locally at the injection site. Post-workout timing is critical because muscles are primed for growth and recovery. Direct intramuscular injection confines effects to the trained muscle group you want to develop.

How is MGF different from PEG-MGF?

Standard MGF has a 5-7 minute half-life requiring daily injections. PEG-MGF (pegylated) lasts much longer (hours). Choose based on protocol preference: frequent localized doses (MGF) or fewer higher-dose injections (PEG-MGF). Effects are similar; administration differs.

Can MGF cause hypoglycemia?

Possibly, though less likely than IGF-1 LR3 due to MGF's very short half-life and localized action. However, the post-workout window and direct muscle injection make hypoglycemia unlikely. Still monitor early use and consume carbs post-injection as a precaution.

How long do I need to use MGF to see muscle growth?

Week 1-2 shows reduced soreness in targeted muscles. Week 4-8 shows noticeable improvements in trained muscle size and recovery capacity. Most users run 8-12 week cycles with equal off-time. Structural gains from satellite cell activation may persist after discontinuation.

For research use only. Nothing on this page is medical advice, and no number here is a recommendation to dose.